Opening of the 2nd tranche of OpPacli™'s preclinical round

Quebec City, October 30th, 2024 - Pharma in silica invites accredited investors interested in a high-risk/high-return endeavor ... and motivated by the improvement of the well-being of persons subjected to chemotherapy treatments.

The second tranche, which could reach $2.5 million, is opened, in complement of the first tranche of $1,5 million previously disbursed by Investissement Québec and new historical shareholders.

The whole team is at work, preparing the regulatory preclinical studies toward the entry of OpPacli™, its lead drug candidate, in a North American clinical study.

The new shareholders will benefit, for a limited time, from the same first tranche's conditions and share price and will obtain identical voting and participating shares. The investment documentation is available upon demand (term sheet, pre-IND package, due diligence reports, etc.).

About Pharma in silica inc.

Laboratoires Pharma in silica inc. is a preclinical-stage pharmaceutical company based in Québec City's Parc Technologique. Since 2019, it has been developing novel treatments for solid cancers (lung, breast, etc.) using OpPacli™, a patented drug nanocarrier. The company is driven by a dynamic group of chemists, pharmacists and managers led by François Arcand, an experienced life sciences entrepreneur (Medicago, Conferences on Plant-made Pharmaceuticals, ERA Biotech). The company established its own research and production facilities and collaborates with oncology experts and world-renowned research centers and has completed the pre-IND/CTA meetings with the FDA and Health Canada.

For more information

François Arcand
President, Pharma in silica inc
514 994 1023 / 418 874-0054 #233
info@pharma-insilica.com

> all news